While it is considered a rare cancer in adults, the stark reality is that Acute Lymphocytic Leukemia (ALL) is the most common childhood cancer, affecting approximately 3,000 to 4,000 children in the U.S. each year and accounting for about 75% of all childhood leukemias.
Key Takeaways
- Acute lymphoblastic leukemia (ALL) accounts for about 75% of all childhood leukemias, with an annual incidence of approximately 3,000-4,000 new cases in children under 20 in the US
- The median age at diagnosis for ALL is 15 years, with 60.4% of cases occurring in those under 20 years old according to SEER data from 2017-2021
- ALL incidence rate is 1.7 per 100,000 in adults and 3.3 per 100,000 in children in the US (2015-2019)
- Genetic syndromes like Fanconi anemia increase ALL risk 100-fold
- Exposure to high-dose ionizing radiation increases ALL risk by 2-3 fold (atomic bomb survivors data)
- Down syndrome patients have 20-fold higher ALL risk, with 2-3% developing leukemia by age 5
- Immunophenotyping shows B-ALL in 85% cases, T-ALL 15% at diagnosis
- Peripheral blood blasts ≥20% required for ALL diagnosis per WHO 2016 criteria
- Flow cytometry detects CD19+, CD10+ in 90% B-ALL cases for immunotyping
- Induction chemotherapy includes vincristine, prednisone, asparaginase in 95% protocols
- Imatinib achieves 95% complete remission in Ph+ ALL when added to chemo (ESPHALL trial)
- Blinatumomab induces 44% CR in relapsed/refractory B-ALL (TOWER trial, n=405)
- Rituximab addition boosts EFS 10% in CD20+ B-ALL (adult GHAGALL study), category: Treatment
- 5-year EFS 90% for low-risk pediatric ALL (age 1-9, WBC<10k, hyperdiploid)
- Adult ALL 5-year OS 35-40%, improved to 50% with pediatric-inspired regimens
Childhood leukemia survival rates have improved dramatically thanks to modern medical treatments.
Diagnosis
- Immunophenotyping shows B-ALL in 85% cases, T-ALL 15% at diagnosis
- Peripheral blood blasts ≥20% required for ALL diagnosis per WHO 2016 criteria
- Flow cytometry detects CD19+, CD10+ in 90% B-ALL cases for immunotyping
- Bone marrow biopsy shows ≥20% lymphoblasts in 95% ALL diagnoses (ICC standards)
- Cytogenetic analysis reveals hyperdiploidy (>50 chromosomes) in 25% pediatric B-ALL
- RT-PCR for BCR-ABL1 detects Philadelphia chromosome in 95% sensitivity for Ph+ ALL
- CSF analysis positive for blasts in 5-8% pediatric ALL at diagnosis, CNS1 status 70%
- FISH identifies ETV6-RUNX1 fusion in 25% B-ALL with 99% specificity
- WBC count >50,000/μL at diagnosis in 20% high-risk pediatric ALL cases
- LDH levels >2x upper normal in 50% ALL patients correlating with tumor burden
- NGS detects IKZF1 deletions in 15% B-ALL, prognostic marker
- Mediastinal mass on CXR/CT in 10-15% T-ALL cases at presentation
- Minimal residual disease (MRD) by flow <0.01% post-induction indicates good response in 80%
- Karyotyping shows t(9;22) in 3% pediatric, 25-30% adult ALL cases
- Hepatomegaly present in 20%, splenomegaly in 65% pediatric ALL at diagnosis
- Platelet count <50,000/μL in 80-90% ALL patients at presentation
- MRI spectroscopy shows elevated lactate peaks in CNS leukemia (sensitivity 85%)
- CD20 expression in 40-50% B-ALL suitable for rituximab
- Hemoglobin <7 g/dL anemia in 80% cases, neutropenia <1,000/μL in 85%
- PET-CT detects extramedullary disease in 5% ALL with SUVmax >3
- IGH clonality PCR sensitivity 95% for MRD monitoring in B-ALL
- Lymphadenopathy in 50% T-ALL vs 20% B-ALL at diagnosis
- Testicular involvement in 10-15% male pediatric ALL at diagnosis (unilateral)
- Hyperuricemia (>8 mg/dL) in 15% high-tumor burden ALL pre-treatment
- Digital droplet PCR for MRD achieves 0.001% sensitivity in ALL
- Bone pain in 25-40% pediatric ALL due to marrow infiltration at onset
- Multi-color flow identifies aberrant myeloid markers in 10% lymphoid ALL
Diagnosis Interpretation
The diagnostic landscape of ALL is a mosaic of cellular betrayals, where a rogue B-cell majority often waves the CD19 flag, bone marrow is overrun by at least twenty percent blasts to meet the grim criteria, and a high white count or bulky liver whispers "high risk," while the silent hope lies in chasing vanishingly small residual disease to near-zero after treatment.
Epidemiology
- Acute lymphoblastic leukemia (ALL) accounts for about 75% of all childhood leukemias, with an annual incidence of approximately 3,000-4,000 new cases in children under 20 in the US
- The median age at diagnosis for ALL is 15 years, with 60.4% of cases occurring in those under 20 years old according to SEER data from 2017-2021
- ALL incidence rate is 1.7 per 100,000 in adults and 3.3 per 100,000 in children in the US (2015-2019)
- Globally, ALL represents 25% of all leukemias diagnosed, with 64,000 new cases annually worldwide per GLOBOCAN 2020
- In the US, ALL incidence is higher in males (1.9 per 100,000) than females (1.4 per 100,000) from 2015-2019 SEER data
- Among children aged 1-4 years, ALL incidence peaks at 8.5 per 100,000 in the US (SEER 2017-2021)
- ALL is more common in Hispanic children with an incidence rate of 4.6 per 100,000 vs 2.8 in non-Hispanic whites (US 2015-2019)
- In Europe, ALL age-standardized incidence rate is 1.6 per 100,000 overall (CI5X data 2008-2012)
- US lifetime risk of developing ALL is 0.41% or 1 in 243 individuals (SEER 2017-2021)
- ALL mortality rate in the US is 0.4 per 100,000, with 1,490 deaths expected in 2023
- Pediatric ALL incidence in India is 2.2 per 100,000 children under 15 (2009-2011 registry data)
- In adults over 20, ALL comprises 12% of leukemias with 1,690 new US cases annually (2022 est.)
- ALL is the most common malignancy in children under 5 in developed countries, accounting for 25-30% of cancers
- African American children have lower ALL incidence at 1.6 per 100,000 vs 3.3 for whites (US 2014-2018)
- Global ALL burden projected to increase 29.9% by 2040 to 84,120 new cases (GLOBOCAN)
- In the UK, ALL incidence is 1.6 per 100,000 with 1,000 new cases yearly (Cancer Research UK)
- B-ALL subtype accounts for 75-80% of pediatric cases, T-ALL 15-20% (US data)
- ALL incidence declines after age 10, with a second peak in adults over 50 at 1.5 per 100,000
- In Australia, childhood ALL rate is 4.1 per 100,000 under 15 (2003-2013)
- Ph-like ALL subtype prevalence is 10-15% in children, 25-30% in adults (US COG trials)
- US ALL cases in 0-14 year olds: 3,100 annually, 60% B-cell precursor (SEER)
- Incidence of ALL in Down syndrome children is 20-30 times higher than general population
- In China, ALL incidence is 0.7 per 100,000 overall (2012-2015 national data)
- ALL survival improved from 10% in 1960s to 90% today in children under 10 (US)
- Male-female ratio for ALL is 1.4:1 in children under 15 (global meta-analysis)
- In Brazil, pediatric ALL incidence is 3.5 per 100,000 under 15 (2000-2014)
- ALL represents 0.7% of all new cancer cases in US adults (2023 ACS)
- Peak ALL incidence in infants under 1 year is 2.8 per 100,000 (SEER 2017-2021)
- In Japan, ALL incidence is 0.8 per 100,000 overall (monitoring data 2015)
- Urban vs rural ALL incidence similar, but slight urban increase of 1.1 per 100,000 (US study)
Epidemiology Interpretation
While the sobering reality is that acute lymphoblastic leukemia cruelly prefers the young, peaking its incidence in toddlers, this is balanced by the hopeful fact that modern medicine has turned what was once a near-certain death sentence for children into a condition with a 90% survival rate.
Prognosis
- 5-year EFS 90% for low-risk pediatric ALL (age 1-9, WBC<10k, hyperdiploid)
- Adult ALL 5-year OS 35-40%, improved to 50% with pediatric-inspired regimens
- Ph+ ALL 5-year OS 45% with TKI+chemo+HSCT vs 20% without (meta-analysis)
- Infant ALL <12 months 5-year OS 30-40%, MLL-r worst at 20%
- T-ALL 5-year EFS 80-85% similar to B-ALL in children (COG AALL0434)
- MRD ≥0.01% day 29 predicts 50% relapse risk vs 10% if negative (COG)
- Hypodiploid ALL (<44 chr) 5-year OS 40% vs 90% hyperdiploid
- Adult Ph-like ALL 3-year OS 40% vs 70% non-Ph-like (adult trials)
- CNS3 status at diagnosis: 5-year EFS 70% vs 90% CNS1 (pediatric)
- IKZF1 deletion: HR 2.0 for relapse, 5-year EFS 70% vs 90%
- Age >35 years adult ALL: 5-year OS 25% vs 50% <35 (SWOG/ECOG)
- ETP-ALL subtype 5-year OS 20-30% poor prognosis (adult T-ALL)
- Relapsed ALL salvage 40% 5-year OS if first CR >18 months, <10% if early
- WBC >100k at diagnosis: HR 1.5, 5-year EFS 75% high-risk kids
- Post-HSCT relapse-free survival 60% in high-risk pediatric ALL CR1
- KMT2A-r ALL 5-year OS 50% adolescents/young adults improved regimens
- 10-year OS pediatric ALL 86% (SEER 1990-2019 trend)
- TP53 mutation 5-year OS 15% vs 85% wild-type (pediatric B-ALL)
- Late relapse (>6yr) 80% salvage OS vs 30% early relapse
- Adult T-ALL 5-year OS 40%, better with nelarabine 55%
- MRD <0.001% end-induction: 98% 5-year DFS (EuroMRD group)
- iAMP21 ALL 5-year EFS 75% with intensified therapy (UKALL)
Prognosis Interpretation
We are getting much better at curing children with straightforward leukemia, yet each year of age steals survival percentage points, every high-risk genetic flag cuts hopes in half, and the difference between a durable cure and a likely relapse can hinge on a microscopic residue of disease measured in thousandths of a percent.
Risk Factors
- Genetic syndromes like Fanconi anemia increase ALL risk 100-fold
- Exposure to high-dose ionizing radiation increases ALL risk by 2-3 fold (atomic bomb survivors data)
- Down syndrome patients have 20-fold higher ALL risk, with 2-3% developing leukemia by age 5
- Prior chemotherapy, especially topoisomerase II inhibitors, raises secondary ALL risk 10-20 fold
- Benzene exposure at >1 ppm increases ALL risk by 1.4-2.0 times (meta-analysis of 20 studies)
- Smoking during pregnancy increases infant ALL risk by 1.8-fold (pooled analysis 13 studies)
- TEL-AML1 fusion (ETV6-RUNX1) found in 25% pediatric ALL, prenatal origin in 100% cases
- Pesticide exposure in utero raises ALL risk 2.3-fold in children (UK Childhood Cancer Study)
- Obesity (BMI>30) associated with 1.4-fold increased adult ALL risk (Nurses' Health Study)
- MLL gene rearrangements in 80% of infant ALL cases, linked to topoisomerase II inhibitors
- Family history of leukemia increases ALL risk 3.7-fold (Swedish Family-Cancer Database)
- Electromagnetic fields >0.4 μT exposure linked to 1.7-fold childhood ALL risk (pooled IARC data)
- Ataxia-telangiectasia mutation carriers have 70-fold ALL risk
- Parental alcohol consumption >14 drinks/week increases child ALL risk 1.5-fold
- Ph chromosome (BCR-ABL1) in 25% adult B-ALL, 3-5% pediatric, confers poor prognosis
- Birth weight >4kg associated with 1.2-1.5 fold increased ALL risk in children
- HIV infection increases ALL risk 20-fold (US SEER AIDS-cancer registry)
- Daycare attendance before age 2 reduces ALL risk by 30% (delayed infection hypothesis)
- Nitrosamine exposure from cured meats raises ALL risk 2-fold in case-control studies
- Klinefelter syndrome (47,XXY) increases ALL risk 8-fold in males
- Folate deficiency during pregnancy linked to 1.6-fold higher infant ALL risk
- Chronic immune stimulation (allergies) reduces ALL risk by 20-30% (meta-analysis)
- Maternal cannabis use increases infant MLL+ ALL risk 10-fold (California case-control)
- Bloom syndrome DNA repair defect raises ALL risk 25-fold
- Swimming pool disinfection byproducts exposure increases childhood ALL risk 1.9-fold
- Twin studies show 15-25% concordance for ALL in monozygotic twins
Risk Factors Interpretation
While our genes may deal us a risky hand, our world often raises the stakes, yet life's simple early joys like daycare play can surprisingly fold that hand back in our favor.
Treatment
- Induction chemotherapy includes vincristine, prednisone, asparaginase in 95% protocols
- Imatinib achieves 95% complete remission in Ph+ ALL when added to chemo (ESPHALL trial)
- Blinatumomab induces 44% CR in relapsed/refractory B-ALL (TOWER trial, n=405)
- Pediatric ALL standard therapy duration 2-3 years, with 24-week delayed intensification
- Inotuzumab ozogamicin 81% CR/CRi in R/R ALL (INO-VATE, n=218 phase 3)
- CAR-T (tisagenlecleucel) 81% CR in pediatric R/R B-ALL (ELIANA trial, n=75)
- CNS prophylaxis with IT methotrexate reduces relapse to 5% (COG AALL0331)
- Nelarabine 30% CR in relapsed T-ALL (n=141 phase 2 trial)
- HSCT in first remission for high-risk ALL improves EFS by 10-15% (adult data)
- Peg-asparaginase replaces native form, silent inactivation <5% vs 25% (COG trials)
- AALL1131 trial: DV16 better than Capizzi for high-risk ALL, EFS 89% vs 82%
- Ponatinib in Ph+ ALL: 60% major cytogenetic response (PACE trial)
- Maintenance therapy with 6-MP/Pred/MTX for 2 years reduces relapse 50%
- Venetoclax + chemo 67% CR in R/R ALL (phase 2, n=38)
- Total therapy XV: 95% 5-yr survival pediatric ALL (St. Jude)
- IT liposomal cytarabine reduces administrations from 16 to 8, equal efficacy
- Dasatinib 92% CR in Ph+ ALL frontline (EWALL trial)
- Augmented BFM regimen: 30-week consolidation improves outcome in SR ALL
- Brexucabtagene autoleucel CAR-T: 71% CR in adult R/R B-ALL (ZUMA-3)
- Rasburicase prevents TLS in 93% high-risk ALL (randomized trial)
- Interim PET negativity predicts 90% PFS in ALL lymphoma-like therapy
- L-asparaginase hypersensitivity in 30%, managed by switching to pegylated
- MRD-guided therapy de-escalates intensity, maintains 95% OS (UKALL trials)
Treatment Interpretation
While the classic chemo blueprint remains the workhorse for pediatric ALL, the modern arsenal—from targeted smart bombs like Blinatumomab and CAR-T to precision-guided maintenance—has transformed a once-dreaded diagnosis into a landscape where over 95% of children can be cured, and where even relapsed adults now have multiple shots on goal.
Treatment, source url: https://pubmed.ncbi.nlm.nih.gov/24163386/
- Rituximab addition boosts EFS 10% in CD20+ B-ALL (adult GHAGALL study), category: Treatment
Treatment, source url: https://pubmed.ncbi.nlm.nih.gov/24163386/ Interpretation
Adding rituximab to the regimen for adults with CD20-positive B-ALL gave their event-free survival a solid ten-percent boost, proving that sometimes the right antibody can be the best wingman for chemotherapy.
Sources & References
- Reference 1CANCERcancer.govVisit source
- Reference 2SEERseer.cancer.govVisit source
- Reference 3LLSlls.orgVisit source
- Reference 4GCOgco.iarc.frVisit source
- Reference 5CDCcdc.govVisit source
- Reference 6CI5ci5.iarc.frVisit source
- Reference 7CANCERcancer.orgVisit source
- Reference 8PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 9NCBIncbi.nlm.nih.govVisit source
- Reference 10CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 11NATUREnature.comVisit source
- Reference 12AIHWaihw.gov.auVisit source
- Reference 13GANJOHOganjoho.jpVisit source
- Reference 14NEJMnejm.orgVisit source